Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Sera Prognostics specializes in women’s health by developing blood-based biomarker tests and predictive analytics to improve pregnancy outcomes. Its core product, the PreTRM test, accurately predicts preterm birth risk, enabling proactive interventions. The company leverages proprietary proteomics, bioinformatics, and extensive biobanks to address unmet needs in maternal-fetal medicine, targeting healthcare providers, payers, and pregnant women worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.